載入...
Alterations in genes other than EGFR/ALK/ROS1 in non-small cell lung cancer: trials and treatment options
During the last decade, we have seen tremendous progress in the therapy of lung cancer. Discovery of actionable mutations in EGFR and translocations in ALK and ROS1 have identified subsets of patients with excellent tumor response to oral targeted agents with manageable side effects. In this review,...
Na minha lista:
| 發表在: | Cancer Biol Med |
|---|---|
| Main Authors: | , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Chinese Anti-Cancer Association
2016
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4850130/ https://ncbi.nlm.nih.gov/pubmed/27144064 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.28092/j.issn.2095-3941.2016.0008 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|